Skip to main content
Erschienen in: Diabetologia 12/2010

01.12.2010 | Article

Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment

verfasst von: O. Kordonouri, E. Pankowska, B. Rami, T. Kapellen, R. Coutant, R. Hartmann, K. Lange, M. Knip, T. Danne

Erschienen in: Diabetologia | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The value of managing children with type 1 diabetes using a combination of insulin pump and continuous glucose monitoring starting from diagnosis for improving subsequent glycaemic control and preserving residual beta cell function was determined.

Methods

A total of 160 children (aged 1–16 years, mean ± SD: 8.7 ± 4.4 years; 47.5% girls) were randomised to receive insulin pump treatment with continuous glucose monitoring or conventional self-monitoring blood glucose measurements. The primary outcome was the level of HbA1c after 12 months. Other analyses included fasting C-peptide, glycaemic variability, sensor usage, adverse events, children’s health-related quality of life and parent’s wellbeing.

Results

HbA1c was not significantly different between the two groups, but patients with regular sensor use had lower values (mean 7.1%, 95% CI 6.8–7.4%) compared with the combined group with no or low sensor usage (mean 7.6%, 95% CI 7.3–7.9%; p = 0.032). At 12 months, glycaemic variability was lower in the sensor group (mean amplitude of glycaemic excursions 80.2 ± 26.2 vs 92.0 ± 33.7; p = 0.037). Higher C-peptide concentrations were seen in sensor-treated 12- to 16-year-old patients (0.25 ± 0.12 nmol/l) compared with those treated with insulin pump alone (0.19 ± 0.07 nmol/l; p = 0.033). Severe hypoglycaemia was reported only in the group without sensors (four episodes).

Conclusion/interpretation

Sensor-augmented pump therapy starting from the diagnosis of type 1 diabetes can be associated with less decline in fasting C-peptide particularly in older children, although regular sensor use is a prerequisite for improved glycaemic control.

Trial registration

ISRCTN.org ISRCTN05450731

Funding

Medtronic International Trading Sàrl, Tolochenaz, Switzerland
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Prince CT, Becker DJ, Costacou T, Miller RG, Orchard TJ (2007) Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 50:2280–2288CrossRefPubMed Prince CT, Becker DJ, Costacou T, Miller RG, Orchard TJ (2007) Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 50:2280–2288CrossRefPubMed
2.
Zurück zum Zitat DCCT Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 128:517–523 DCCT Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 128:517–523
3.
Zurück zum Zitat Ludvigsson J (2009) C-peptide an adequate endpoint in type 1 diabetes. Diabetes Metab Res Rev 25:691–693CrossRefPubMed Ludvigsson J (2009) C-peptide an adequate endpoint in type 1 diabetes. Diabetes Metab Res Rev 25:691–693CrossRefPubMed
4.
Zurück zum Zitat Levin BS, Anderson BJ, Butler DA, Antisdel JE, Brackett J, Laffel LMB (2001) Predictors of glycaemic control and short-term adverse outcomes in youth and with type 1 diabetes. J Pediatr 139:197–203CrossRef Levin BS, Anderson BJ, Butler DA, Antisdel JE, Brackett J, Laffel LMB (2001) Predictors of glycaemic control and short-term adverse outcomes in youth and with type 1 diabetes. J Pediatr 139:197–203CrossRef
5.
Zurück zum Zitat Deiss D, Bolinder J, Riveline J-P et al (2006) Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diab Care 29:2730–2732CrossRef Deiss D, Bolinder J, Riveline J-P et al (2006) Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diab Care 29:2730–2732CrossRef
6.
Zurück zum Zitat Danne T, de Valk HW, Kracht T et al (2009) Reducing glycaemic variability in type 1 diabetes self-management with a continuous glucose monitoring system based on wired enzyme technology. Diabetologia 52:1496–1503CrossRefPubMed Danne T, de Valk HW, Kracht T et al (2009) Reducing glycaemic variability in type 1 diabetes self-management with a continuous glucose monitoring system based on wired enzyme technology. Diabetologia 52:1496–1503CrossRefPubMed
7.
Zurück zum Zitat The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2008) Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 359:1464–1476CrossRef The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2008) Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 359:1464–1476CrossRef
8.
Zurück zum Zitat Service FJ, Molnar GD, Rosevear, Ackermann E, Gatweood LC, Taylor WF (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644–655PubMed Service FJ, Molnar GD, Rosevear, Ackermann E, Gatweood LC, Taylor WF (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644–655PubMed
9.
Zurück zum Zitat Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, Klingensmith GJ (2009) ISPAD Clinical Practice Consensus Guidelines 2009. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diab 10(suppl 12):71–81CrossRef Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, Klingensmith GJ (2009) ISPAD Clinical Practice Consensus Guidelines 2009. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diab 10(suppl 12):71–81CrossRef
10.
Zurück zum Zitat The Disabkids Group Europe: The Disabkids questionnaires. Quality of life questionnaires for children with chronic conditions. Lengerich: Pabst Science Publishers The Disabkids Group Europe: The Disabkids questionnaires. Quality of life questionnaires for children with chronic conditions. Lengerich: Pabst Science Publishers
11.
Zurück zum Zitat The KIDSCREEN Group Europe. The KIDSCREEN Questionnaires. Quality of life questionnaires for children and adolescents. Lengerich: Pabst Science Publishers The KIDSCREEN Group Europe. The KIDSCREEN Questionnaires. Quality of life questionnaires for children and adolescents. Lengerich: Pabst Science Publishers
12.
Zurück zum Zitat Rajmil L, Alonso J, Berra S, KIDSCREEN Group et al (2006) Use of a children questionnaire of health-related quality of life (KIDSCREEN) as a measure of needs for health care services. J Adolesc Health 38:511–518CrossRefPubMed Rajmil L, Alonso J, Berra S, KIDSCREEN Group et al (2006) Use of a children questionnaire of health-related quality of life (KIDSCREEN) as a measure of needs for health care services. J Adolesc Health 38:511–518CrossRefPubMed
13.
Zurück zum Zitat World Health Organization, Regional Office for Europe (2008) Wellbeing measures in primary health care/the DEPCARE project: report on a WHO meeting, Stockholm, Sweden, 12–13 February 1998. WHO Regional Office for Europe, Copenhagen World Health Organization, Regional Office for Europe (2008) Wellbeing measures in primary health care/the DEPCARE project: report on a WHO meeting, Stockholm, Sweden, 12–13 February 1998. WHO Regional Office for Europe, Copenhagen
14.
Zurück zum Zitat Pozzilli P, Crino A, Schiaffini R, IMDIAB Group et al (2003) A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8). Diab Techn Therap 5:965–974CrossRef Pozzilli P, Crino A, Schiaffini R, IMDIAB Group et al (2003) A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8). Diab Techn Therap 5:965–974CrossRef
15.
Zurück zum Zitat Mortensen HB, Swift PG, Holl RW, and Hvidoere Study Group on Childhood Diabetes et al (2009) Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes 11:218–226CrossRef Mortensen HB, Swift PG, Holl RW, and Hvidoere Study Group on Childhood Diabetes et al (2009) Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes 11:218–226CrossRef
16.
Zurück zum Zitat Wysocki T, Iannoti R, Weissberg-Benchell J, Family Management of Childhood Diabetes Steering Committee et al (2008) Diabetes problem solving by youths with type 1 diabetes and their caregivers: measurement, validation, and longitudinal associations with glycemic control. J Pediatr Psychol 33:875–884CrossRefPubMed Wysocki T, Iannoti R, Weissberg-Benchell J, Family Management of Childhood Diabetes Steering Committee et al (2008) Diabetes problem solving by youths with type 1 diabetes and their caregivers: measurement, validation, and longitudinal associations with glycemic control. J Pediatr Psychol 33:875–884CrossRefPubMed
17.
Zurück zum Zitat Insabella G, Grey M, Knafl G, Tamborlane W (2007) The transition to young adulthood in youth with type 1 diabetes on intensive treatment. Pediatr Diabetes 8:228–234CrossRefPubMed Insabella G, Grey M, Knafl G, Tamborlane W (2007) The transition to young adulthood in youth with type 1 diabetes on intensive treatment. Pediatr Diabetes 8:228–234CrossRefPubMed
18.
Zurück zum Zitat Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598–2608CrossRefPubMed Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598–2608CrossRefPubMed
19.
Zurück zum Zitat Ludvigsson J, Faresjö M, Hjorth M et al (2008) GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359:1909–1920CrossRefPubMed Ludvigsson J, Faresjö M, Hjorth M et al (2008) GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359:1909–1920CrossRefPubMed
20.
Zurück zum Zitat The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2009) Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diab Care 32:1947–1953CrossRef The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2009) Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diab Care 32:1947–1953CrossRef
21.
22.
Zurück zum Zitat Bullinger M, Schmidt S, Petersen C (2002) Assessing quality of life of children with chronic health conditions and disabilities: a European approach. Int J Rehabil Res 25:197–206CrossRefPubMed Bullinger M, Schmidt S, Petersen C (2002) Assessing quality of life of children with chronic health conditions and disabilities: a European approach. Int J Rehabil Res 25:197–206CrossRefPubMed
23.
Zurück zum Zitat Bergenstal RM, Tamborlane WV, Ahmann A et al (2010) Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 363:311–320CrossRefPubMed Bergenstal RM, Tamborlane WV, Ahmann A et al (2010) Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 363:311–320CrossRefPubMed
24.
Zurück zum Zitat Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G, EURODIAB Study Group (2009) Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet 373:2027–2033CrossRefPubMed Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G, EURODIAB Study Group (2009) Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet 373:2027–2033CrossRefPubMed
25.
Zurück zum Zitat Danne T, Mortensen HB, Hougaard P, Hvidøre Study Group on Childhood Diabetes et al (2001) Persistent differences among centres over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidøre Study Group. Diab Care 24:1342–1347CrossRef Danne T, Mortensen HB, Hougaard P, Hvidøre Study Group on Childhood Diabetes et al (2001) Persistent differences among centres over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidøre Study Group. Diab Care 24:1342–1347CrossRef
26.
Zurück zum Zitat White NH, Sun W, Cleary PA et al (2008) Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 126:1707–1715CrossRefPubMed White NH, Sun W, Cleary PA et al (2008) Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 126:1707–1715CrossRefPubMed
Metadaten
Titel
Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment
verfasst von
O. Kordonouri
E. Pankowska
B. Rami
T. Kapellen
R. Coutant
R. Hartmann
K. Lange
M. Knip
T. Danne
Publikationsdatum
01.12.2010
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 12/2010
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1878-6

Weitere Artikel der Ausgabe 12/2010

Diabetologia 12/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.